Table 2 Average and percentage of PSA and PSMA PET metrics in the whole cohort
Clinical and imaging metrics | Visit 1 (n = 9) | Visit 2 (n = 9) | % change visit 1–2 | Outcome at 1-year | p* | Visit 3 (n = 5) | % change visit 1–3 | Outcome at 1-year | p* | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unfavorable (n = 6) | Favorable (n = 3) | Unfavorable (n = 2) | Favorable (n = 3) | |||||||||
PSA (ng/mL) | Average (SD) | 30.79 (37.74) | 35.84 (49.40) | − 12% (0.39) | n/a | n/a | 0.82 | 34.03 (66.66) | − 42% (0.59) | n/a | n/a | 0.88 |
n + 10% | – | 2 (#6, #9) | 45% | 1 | 1 | 1 (#6) | 36% | – | 1 | |||
n stable | – | 1 (#7) | 7% | 1 | – | – | – | – | – | |||
n − 10% | – | 6 (#1, #2, #3, #4, #5, #8) | − 34% | 4 | 2 | 4 (#1, #3, #5, #7) | − 68% | 2 | 2 | |||
PSMA-VOL (mL) | Average (SD) | 442.00 (562.69) | 523.73 (6676.88) | 5% (0.21) | n/a | n/a | 0.08 | 43.78 (56.19) | − 16% (0.35) | n/a | n/a | 0.38 |
n + 10% | 3 (#2, #4, #9) | 21% | 3 | – | 1 (#7) | 13% | 1 | – | ||||
n stable | – | 5 (#3, #5, #6, #7, #8) | 5% | 3 | 2 | 3 (#3, #5, #6) | − 6% | 1 | 2 | |||
n − 10% | – | 1 (#1) | − 37% | – | 1 | 1 (#1) | − 67% | – | 1 | |||
SUVmean | Average (SD) | 8.31 (2.85) | 8.34 (2.78) | 3% (0.17) | n/a | n/a | 0.29 | 7.75 (3.71) | − 15% (0.33) | n/a | n/a | 0.38 |
n + 10% | – | 2 (#3, #7) | 17% | 2 | – | 1 (#3) | 14% | 1 | – | |||
n stable | – | 6 (#2, #4, #5, #6, #8, #9) | 5% | 4 | 2 | 3 (#5, #6, #7) | − 6% | 1 | 2 | |||
n − 10% | – | 1 (#1) | 37% | – | 1 | 1 (#1) | –62% | – | 1 | |||
SUVmax | Average (SD) | 29.34 (14.91) | 33.24 (19.97) | 10% (0.06) | n/a | n/a | 0.141 | 25.33 (20.79) | − 17% (0.17) | n/a | n/a | 1 |
n + 10% | – | 6 (#2, #3, #4, #7, #8, #9) | 24% | 6 | – | 1 (#7) | 25% | 1 | – | |||
n stable | – | 2 (#5, #6) | − 2% | 1 | 1 | 3 (#5, #3, #6) | 1% | 1 | 2 | |||
n − 10% | – | 1 (#1) | − 47% | – | 1 | 1 (#1) | − 73% | – | 1 | |||